Cancer Research Technology
Log in Register
Menu
Search
Recombinant Antibodies

Anti-Cisplatin modified DNA, Recombinant [CP9/19]

Invented by Dr Michael Tilby from University of Newcastle upon Tyne
Invented at University of Newcastle upon Tyne , The Institute of Cancer Research
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Anti-Cisplatin modified DNA, Recombinant [CP9/19]
Add an image
Sonicated DNA was prepared from yeast strain (No-247) BY4742 treated with Cisplatin (2.5 mM, 4 hour incubation). Immunoprecipitation was performed using an increasing amount of anti-Cisplatin modified DNA [CP9/19] (top panel) and anti-Cisplatin modified DNA, Recombinant [CP9/19] (lower panel). Fold enrichment over no antibody control is shown on the Y axis with the amount of antibody indicated (in ug) on the X axis. Data kindly provided by Drs. Simon Reed and Shuvro Prokash Nandi.
Add an image
Image thumbnail for Anti-Cisplatin modified DNA, Recombinant [CP9/19]
Catalogue Number 152732
Applications ELISA IHC IP DB
Antigen/Gene or Protein Targets Cisplatin modified native DNA
Reactivity N/A
Relevance This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
Host Rat
Subclass IgG2a kappa
Positive Control RNA/DNA
Research Area DNA Damage and Repair, Epigenetics & Nuclear Signalling
Notes Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Three different variants available:
- Anti-Cisplatin modified DNA [CP9/19], Rat IgG2a, Kappa
- Anti-Cisplatin modified DNA [CP9/19], Rat IgG2a, Kappa, containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-Cisplatin modified DNA [CP9/19], Rabbit IgG, Kappa.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Europe PMC ID: 1703029

View  

Original hybridoma first published in: Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.

View  

Add a reference

References: 2 entries

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

View  

Original hybridoma first published in: Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.

View  

Add a reference

Inventor Information